TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03690401

Intervention type: DEVICE
Intervention: SOZO Device
Description: SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. Participants will be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes. A total of 5 SOZO measurements will be recorded over 12 weeks.

Intervention type: DEVICE
Intervention: SOZO Device
Description: SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. Participants will be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes. A total of 5 SOZO measurements will be recorded over 12 weeks.

Intervention type: DEVICE
Intervention: DEXA Scan
Description: DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.

Intervention type: DEVICE
Intervention: DEXA Scan
Description: DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
Study: NCT00600106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1/10 NA/EE
Description: Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mg placebo
Study: NCT04053855

Intervention type: BIOLOGICAL
Intervention: Urinary sample
Description: Urinary sample (100 ml) will be collected in the urology department to analysis urinary exosomes.

Intervention type: BIOLOGICAL
Intervention: Urinary sample
Description: Urinary sample (100 ml) will be collected in the urology department to analysis urinary exosomes.
Study: NCT02810288

Intervention type: BEHAVIORAL
Intervention: Voluntarily response all items in the questionnaire.
Description: The study type is a cross-sectional study, by means of electronic self-administered survey as online questionnaire sent by e-mail.~The questionnaire for the survey was developed with reference to previously published guidelines on the design of questionnaire surveys. The content validity of the questionnaire was verified by review of clinicians not participating into the project and by a statistician.

Intervention type: BEHAVIORAL
Intervention: Voluntarily response all items in the questionnaire.
Description: The study type is a cross-sectional study, by means of electronic self-administered survey as online questionnaire sent by e-mail.~The questionnaire for the survey was developed with reference to previously published guidelines on the design of questionnaire surveys. The content validity of the questionnaire was verified by review of clinicians not participating into the project and by a statistician.
Study: NCT06300749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Cervical Manipulation
Description: In the chiropractic cervical manipulation group, the patient was placed in the supine position. The therapist moved to the patient's head, identified the C5-C6 segment by palpation, and manually performed spinal manipulation from the right side using the cervical rotary break/index push technique since the dominant side of the patients was the right extremity. In the cervical rotary break/index thrust technique, the lateral aspect of the practitioner's index finger was placed in contact with the posterior aspect of the participant's C5 facet joint, and a rotational thrust was performed between the C5-C6 vertebrae.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Technique Practice
Description: The sham technique can be defined as a technique that does not have any therapeutic effect and is preferred to determine whether the efficacy of another technique is superior. The patient was placed in the supine position. The therapist moved to the patient's head, and the C5-C6 segment localized in the lower cervical region was detected by palpation. The C5-C6 segment was positioned to perform chiropractic cervical manipulation and waited for 30 seconds without any pushing force.
Study: NCT01277705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine
Description: Intramuscular, single

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix™
Description: Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' IPV vaccine
Description: Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Revaxis®
Description: Intramuscular, single dose
Study: NCT06547697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate sodium concentration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate sodium concentration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate sodium concentration
Study: NCT00869492

Intervention type: DRUG
Group type: OTHER
Intervention: benzoyl peroxide
Description: benzoyl peroxide %5 solution once dailly

Intervention type: DRUG
Group type: OTHER
Intervention: nadifloxacine
Description: Nadifloxacine 1% cream twice dailly

Intervention type: DRUG
Group type: OTHER
Intervention: nadifloxacine
Description: Nadifloxacine 1% cream twice dailly
Study: NCT03989375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve electric stimulator
Description: The stimulator that can be attached to ears of the patient.We suppose that this device can reduce the incidence of perioperative neurocognitive disorders(PND)
Study: NCT00795444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc
Description: Maraviroc (INN), 300 mg tablets. A dose of 300 mg will be administered every 12 hours.
Study: NCT01282242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV rt-PA
Description: open-label
Study: NCT01375127

Intervention type: DRUG
Intervention: Tofacitinib
Description: Subjects who previously took 15 mg BID or 30 mg BID

Intervention type: DRUG
Intervention: Tofacitinib
Description: Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID
Study: NCT02200757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin
Description: 230 mg/m2 (170 mg/m2 doxorubicin equivalent) intravenously on Day 1 of each 21-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: 1.5 mg/m2/day intravenously for 5 consecutive days on Day 1 of each 21-day cycle OR 4 mg/m2 intravenously on Days 1, 8 and 15 of each 28-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs
Study: NCT00551434

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Creatine 21 g daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine and creatine
Description: L-arginine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: l-arginine
Description: l-arginine 9 g daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo, double
Description: placebo
Study: NCT01631201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifalazil 25 milligram
Description: Single dose of 25 milligram rifalazil to be administered on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 1 gram
Description: Single dose of Azithromycin 1 gram to be administered on Day 1.
Study: NCT03127917

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: L-citrulline capsules given at 6 g/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: L-citrulline capsules given at 6 g/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Maltodextrin capsules given as placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Maltodextrin capsules given as placebo
Study: NCT01404143

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subscapularis Tenotomy
Description: After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity. The tendon will be tagged for later repair. Repair will take place with a combination of transosseous sutures (3) placed in a mattress configuration through the area of exposed lesser tuberosity. In addition, a soft tissue tendon to tendon repair will be carried out using figure-8 stitches using #2 (heavy) non-absorbable suture (Ticron).
Study: NCT03234075

Intervention type: OTHER
Intervention: Regional organization for promotion of renal transplantation
Description: Early identification of candidates for renal transplantation~* with the help of a care coordinator Inform all patients appropriately about the techniques of renal function supplementation~* delivered by expert patients and a care coordinator Assist the nephrologists in patient graft pathway~* Multidisciplinary assessment of patients in dedicated web-conferencing meetings bringing together nephrologists and transplant team ( WebRCP of kidney transplant orientation)~* Helping to carry out the pre-graft assessments of patients by a care coordinator
Study: NCT01092364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Description: Behavioral lifestyle intervention for weight loss, compared to advice-only control.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Description: Behavioral lifestyle intervention for weight loss, compared to advice-only control.
Study: NCT04011137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Arm-cranking exercise
Study: NCT02000089

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tumor marker gene test with CA19-9
Description: A tumor marker gene test that will be used to stratify individuals into one of several circulating tumor marker reference ranges for CA19-9. The variants in the genes FUT3 and FUT2 affect the levels of CA19-9.
Study: NCT00951691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced acute medical rehabilitation
Description: Daily up to 3-hour sessions of enhanced physical and occupational therapies (see Lenze et al, Enhanced Medical Rehabilitation Increases Therapy Intensity and Engagement and Improves Functional Outcomes in Postacute Rehabilitation of Older Adults: A Randomized-Controlled Trial. J American Medical Director's Association, 2012 for details and outcome data.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard treatment with physical and occupational therapies
Study: NCT01614522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN001
Description: ASLAN001 500mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN001
Description: ASLAN001 500mg BID
Study: NCT02650193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSP-130
Description: Dosage will vary per each cohort: (Five independent cohorts) Cycle 0 Regimen A - 3 mg Cycle 0 Regimen B - 6 mg Cycles 1-4 Regimen B - 6 mg Cycles 1-4 Regimen A (Potential)- 3 mg Cycles 1-4 Regimen C (Conditional)- 12 mg
Study: NCT00470873

Intervention type: DRUG
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Primary care erectile dysfunction patients for whom physician decided to start the treatment with vardenafil
Study: NCT03164122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of microfat and plasma rich platelet PRP
Description: intra-articular injections

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI 3T
Study: NCT02626299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid - 800mg/day
Description: All participants will take 1000 mg/DHA per day (1 capsule will be labeled with 200 mg; 2 capsules will be masked with 400 mg each)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid - 200mg/day
Description: The control group will receive 1-capsule containing 200 mg DHA/d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docosahexaenoic acid - 200mg/day
Description: The control group will receive 1-capsule containing 200 mg DHA/d.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 2 capsules (masked) containing half soybean oil and half corn oil equaling 800 mg.The soybean and corn oil combination does not contain DHA.
Study: NCT02334137

Intervention type: BEHAVIORAL
Intervention: iPad app
Description: Provided by the Patient Education Institute, the X-plain iPad app includes modules on healthy eating for diabetics, eye complications, foot care, and others.

Intervention type: BEHAVIORAL
Intervention: iPad app
Description: Provided by the Patient Education Institute, the X-plain iPad app includes modules on healthy eating for diabetics, eye complications, foot care, and others.

Intervention type: BEHAVIORAL
Intervention: iPad app
Description: Provided by the Patient Education Institute, the X-plain iPad app includes modules on healthy eating for diabetics, eye complications, foot care, and others.

Intervention type: BEHAVIORAL
Intervention: Educator sessions
Description: A certified diabetes educator and/or registered dietitian will meet with patients for 30-60 minutes prior to their ophthalmology visits, when scheduling permits.

Intervention type: BEHAVIORAL
Intervention: Educator sessions
Description: A certified diabetes educator and/or registered dietitian will meet with patients for 30-60 minutes prior to their ophthalmology visits, when scheduling permits.

Intervention type: BEHAVIORAL
Intervention: Retinal photos
Description: A resident ophthalmologist will spend approximately 5 minutes showing patient their own retinal photos, compared to a normal retina, and explaining the pathology present (if applicable).
Study: NCT00589602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood lymphocyte therapy
Description: T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be \>0.5 x 105 but \<1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be \>2 x 106 cells/kg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Allogeneic Hematopoietic Stem Cell Transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation (TBI)
Description: Treatment will be delivered using 6MV photons twice daily for 3 days
Study: NCT03952689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Serenno Medical Automatic Urine Output measuring device
Description: Device that measures ongoing urine output will be connecter to the patients catheter. The urine count of the device will be compared to the gold standard measurement technique (nurse count).
Study: NCT04218513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Edaravone Injection
Description: 30 min intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone Injection
Description: 30 min intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-Aminoethanesulfonic Acid Injection
Description: 30 min intravenous infusion
Study: NCT03391375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 & AIDSVAX B/E
Description: DNA-HIV-PT123 encodes clade C ZM96 Gag and gp140, CN54 Pol-Nef; AIDSVAX®B/E is a subtype B (MN) and subtype E (A244) HIV gp120 glycoprotein adsorbed onto aluminium hydroxide gel adjuvant
Study: NCT04143789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP-002
Description: Dose escalation
Study: NCT03062670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retreat
Description: Full day off-site training session
Study: NCT04520295

Intervention type: GENETIC
Intervention: ctDNA screening
Description: Molecular events including gene mutation, fusion and amplification will be detected by next generation sequencing platform (OncoScreen Plus panelTM) using ctDNA collected from peripheral blood samples of gastric cancer patients. For HER2 positive patients, samples will be collected at baseline, first surveillance after treatment and disease progression. For HER2 negative patients, samples will be collected at baseline as negative control.
Study: NCT03552809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gigaa Cheese 810 nm Diode Laser
Description: Diode Laser assisted frenectomy operation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gigaa Cheese 810 nm Diode Laser
Description: Diode Laser assisted frenectomy operation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Frenectomy Operation
Description: Frenectomy operation performed by surgical blades with suturing.
Study: NCT03857464

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Near Patient Testing
Description: Near-patient testing will be conducted at Foothills Hospital rapid response lab. Negative results using C. DIFF QUIK CHEK COMPLETE® will be reported immediately to the patient wards. Positive results will be confirmed using nucleic acid testing at the centralized testing facility.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Near Patient Testing
Description: Near-patient testing will be conducted at Foothills Hospital rapid response lab. Negative results using C. DIFF QUIK CHEK COMPLETE® will be reported immediately to the patient wards. Positive results will be confirmed using nucleic acid testing at the centralized testing facility.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SOP for C. difficile diagnostics
Description: Two-step testing algorithm for Clostridium difficile at centralized testing facilities. No change from the current protocol.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SOP for C. difficile diagnostics
Description: Two-step testing algorithm for Clostridium difficile at centralized testing facilities. No change from the current protocol.
Study: NCT00748111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample and thrombus sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample and thrombus sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample and thrombus sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample and thrombus sample
Study: NCT00343395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVANDAMET
Description: 2/500 mg
Study: NCT03781596

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Symptom Survey
Description: Patient will complete symptom survey prior to starting the study drugs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Compliance Phone Call
Description: The patient will receive a phone call at 4 weeks to evaluate medication compliance including the number on the inhaler and the number of pills remaining in the container.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Medication Compliance Phone Call
Description: The patient will receive a phone call at 4 weeks to evaluate medication compliance including the number on the inhaler and the number of pills remaining in the container.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoscopy while on study drug
Description: Endoscopy will be performed after 8 weeks of therapy. Endoscopic scoring will be assigned and the histology will be evaluated, including eotaxin 3 staining. The change in eosinophil count and eotaxin staining will be measured.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopy while on study drug
Description: Endoscopy will be performed after 8 weeks of therapy. Endoscopic scoring will be assigned and the histology will be evaluated, including eotaxin 3 staining. The change in eosinophil count and eotaxin staining will be measured.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom Survey
Description: The patient will complete a symptom survey after 8 weeks on the study drugs, and the change in survey score will be measured.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Symptom Survey
Description: The patient will complete a symptom survey after 8 weeks on the study drugs, and the change in survey score will be measured.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Participants in the experimental and placebo arms will be given swallowed fluticasone for an 8 week course. Doses determined by age and weight.
Study: NCT01404143

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subscapularis peel
Description: The subscapularis will be elevated from the lesser tuberosity. The tendon will be tagged with stay sutures for later reattachment (3 sutures in mattress configuration). Reapproximation will take place with three non-absorbable mattress sutures placed in a trans-osseous fashion through the bicipital groove, exiting the greater tuberosity and tied over a 4-hole mini-fragment plate.
Study: NCT02453152

Intervention type: OTHER
Intervention: History and physical
Description: Subjects will undergo a physical exam and medical history review, including review of genetic test results.

Intervention type: OTHER
Intervention: Tidal breathing
Description: Subjects' breathing patterns will be evaluated at rest and at reduced/eliminated ventilator support.

Intervention type: OTHER
Intervention: Maximal respiratory pressures
Description: Subjects' strongest inspiratory and expiratory pressures will be measured.